Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna's (MRNA) COVID-19 vaccine continues to enjoy robust demand. The company delivered 199 million doses of its COVID-19 vaccine during the second quarter.

Moderna (MRNA) Q2 Earnings Top, COVID-19 Vaccine Brings $4.2B

"We really do believe the virus is here to stay for the long term," a top Moderna executive said.

Moderna says we'll need COVID-19 booster shots this fall, predicting protection will wane from its vaccine

According to study results released with Moderna (NASDAQ: MRNA) Q2 2021 earnings report, its COVID-19 vaccine booster has a strong antibody response against the delta variant of the virus. However, the company said that with people going inside following the summer, the contagious delta strain is likely to increase to infections breakout in people that have […] The post Moderna releases earnings and talks about booster COVID-19 shots appeared first on Invezz.

Moderna releases earnings and talks about booster COVID-19 shots

Moderna (MRNA) delivered earnings and revenue surprises of 7.49% and 1.45%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Q2 Earnings and Revenues Top Estimates

The stock price of Moderna Inc (NASDAQ: MRNA) fell by over 5% pre-market. This is why it happened.

MRNA Stock Price Falls Over 5% Pre-Market: Why It Happened

The highly contagious delta variant will lead to an increase in breakthrough infections among the fully vaccinated as people begin moving indoors, Moderna said.

Delta variant will lead to increase in breakthrough Covid infections among vaccinated, Moderna says

Moderna Inc.'s said Thursday that its COVID-19 vaccine is 93% efficacious six months after the second dose as part of its second-quarter earnings announcement. This is different than what Pfizer Inc. said last week about its COVID-19 shot, which is that immunity can wane to 83.7% four to six months after getting the second shot.

Moderna says its COVID-19 shot provides 93% immunity after six months

Moderna said its Covid-19 vaccine booster shot produced a “robust” antibody response against the highly contagious delta variant.

Moderna says its Covid vaccine booster produced ‘robust' immune response against delta

The mRNA specialist reported a larger-than-expected profit, but that wasn't enough for investors following a 141% gain over the past three months.

Moderna Earnings Topped Expectations. Why Its Stock Is Dropping.

Moderna Inc. reported Thursday that it swung to a second-quarter profit that was well above expectations, as better-than-forecast product sales were boosted by sales of 199 million doses of the biotechnology company's COVID-19 vaccine. The stock slipped 0.4% in premarket trading, after soaring 20.9% the past two days to close at a record $419.05 on Wednesday.

Moderna swings to big Q2 profit beat, as 199 million doses of COVID-19 vaccine were sold

Moderna Inc said on Thursday its COVID-19 shot was about 93% effective four to six months after the second dose, showing hardly any change from the 94% efficacy reported in its original clinical trial.

Moderna says its COVID-19 shot remains 93% effective 4-6 months after second dose

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna releases second quarter earnings and clinical update

Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates

Gilead Sciences

Regeneron Pharmaceuticals

All three have blockbuster products already on the market.

3 Biotech Stocks That Could Make You Richer in August (and Beyond)

Mounting COVID-19 case counts could drive more people to get vaccinated.

Why Moderna Stock Surged to a New All-Time High Today

A sizable number of purchased call options and sold put options remain the open interest for MRNA, and option premiums are unusually high right now.

Moderna (MRNA) Option Traders Ready for Earnings Boost

BioNTech SE

Moderna, Inc. (NASDAQ: MRNA) and BioNTech SE (NASDAQ: BNTX) shares have been on tear ever since these companies embarked on their respective COVID-19 vaccine programs. Shares of both companies are trading just shy of their all-time highs.

Moderna Vs. BioNTech: How Do These High-Flying COVID-19 Vaccine Stocks Compare?

Earnings Preview: What To Expect From Moderna On Thursday. Here's What To Expect.

Earnings Preview: What To Expect From Moderna On Thursday

Moderna and BioNTech have climbed in recent weeks as the resurgent Delta variant has captured headlines.

Moderna and BioNTech stocks are surging amid reports of FDA vaccine-approval progress

Illumina

Johnson & Johnson

Novartis

Zoetis

Let us take a look at what is in store for some of the drug/biotech stocks, which are scheduled to report on Aug 5.

Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN

Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Moderna (MRNA) This Earnings Season?

Hecla Mining

ViacomCBS

Earnings reports released Tuesday morning were again overwhelmingly positive, with the vast majority of companies reporting profits that beat consensus estimates.

Earnings Previews: Hecla Mining, Moderna, ViacomCBS

Moderna stock rallied by more than 12% since our last update on July 19 and remains up by almost 50% over the last month. The gains are driven largely by the inclusion of the stock into the S&P 500 index from July 21, which, in turn, drove demand from index funds and likely from managed funds that.

What's New With Moderna Stock?

The FDA granted Fast Track designation Moderna Inc's (NASDAQ: MRNA) mRNA-1345, its investigational single-dose mRNA vaccine against the respiratory syncytial virus (RSV) in adults older than 60 years of age. The respiratory syncytial virus is a common respiratory virus that generally causes cold-like symptoms.

Moderna RSV-Targeted mRNA Vaccine Candidate Gets Fast Track Tag In US

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna receives FDA Fast Track designation for Respiratory Syncytial Virus (RSV) vaccine (mRNA-1345).

Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) Vaccine (mRNA-1345)

Pfizer

These elements may represent billions of dollars in the months and years to come.

News for Moderna Stock (MRNA)